These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

862 related articles for article (PubMed ID: 27548334)

  • 21. Evaluation of the relationship between splenic iron overload and liver, heart and muscle features evident on T2*-weighted magnetic resonance imaging.
    Çetinçakmak MG; Hattapoğlu S; Söker M; Ekici F; Yilmaz K; Göya C; Hamidi C
    Adv Clin Exp Med; 2020 Apr; 29(4):475-480. PubMed ID: 32369274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MRI assessment of excess cardiac iron in thalassemia major: When to initiate?
    Chen X; Zhang Z; Zhong J; Yang Q; Yu T; Cheng Z; Chan Q; Guo H; Liang B
    J Magn Reson Imaging; 2015 Sep; 42(3):737-45. PubMed ID: 26154874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erythrocytapheresis limits iron accumulation in chronically transfused sickle cell patients.
    Hilliard LM; Williams BF; Lounsbury AE; Howard TH
    Am J Hematol; 1998 Sep; 59(1):28-35. PubMed ID: 9723573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.
    Ha SY; Mok AS; Chu WC; Raskalkar DD; Cheuk DK; Chiang AK; Ho MH; Chan GC
    Hemoglobin; 2009; 33(5):323-31. PubMed ID: 19814678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
    Koren A; Fink D; Admoni O; Tennenbaum-Rakover Y; Levin C
    Eur J Haematol; 2010 Jan; 84(1):72-8. PubMed ID: 19732137
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Growth differentiation factor-15 in young sickle cell disease patients: relation to hemolysis, iron overload and vascular complications.
    Tantawy AA; Adly AA; Ismail EA; Darwish YW; Ali Zedan M
    Blood Cells Mol Dis; 2014 Dec; 53(4):189-93. PubMed ID: 25065856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Value of magnetic resonance imaging T2* tests in detecting heart and liver iron overload in patients with β-thalassemia major].
    Wu X; Jing Y; Pei F; Chen J; Feng X; He Y; Zhang Y; Li C
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Feb; 33(2):249-52. PubMed ID: 23443782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Consequences and management of iron overload in sickle cell disease.
    Porter J; Garbowski M
    Hematology Am Soc Hematol Educ Program; 2013; 2013():447-56. PubMed ID: 24319218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Liver and heart iron deposition status in patients with β thalassemia major: a multicenter study].
    Li C; Liu S; Wang Y; Wen F; Gao H; Chen G; Li C; Wu X; Fang J; Hao W; Liu R; Zhang X; Chu CW; Au W
    Zhonghua Er Ke Za Zhi; 2014 Feb; 52(2):90-3. PubMed ID: 24739717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Magnetic resonance imaging during management of patients with transfusion-dependent thalassemia: a single-center experience.
    Karakas Z; Yilmaz Y; Bayramoglu Z; Karaman S; Aydogdu S; Karagenc AO; Tugcu D; Dursun M
    Radiol Med; 2018 Aug; 123(8):572-576. PubMed ID: 29663188
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum angiogenin level in sickle cell disease and beta thalassemia patients.
    Matter RM; Abdelmaksoud AA; Shams MA; Bebawy EK
    Pediatr Hematol Oncol; 2014 Feb; 31(1):50-6. PubMed ID: 24483841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Phase II, Multicenter, Single-Arm Study to Evaluate the Safety and Efficacy of Deferasirox after Hematopoietic Stem Cell Transplantation in Children with β-Thalassemia Major.
    Yesilipek MA; Karasu G; Kaya Z; Kuskonmaz BB; Uygun V; Dag I; Ozudogru O; Ertem M
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):613-618. PubMed ID: 29155313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of cardiac and hepatic iron overload in thalassemia major patients with T2* magnetic resonance imaging.
    Wahidiyat PA; Liauw F; Sekarsari D; Putriasih SA; Berdoukas V; Pennell DJ
    Hematology; 2017 Sep; 22(8):501-507. PubMed ID: 28218005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T2-star (T2*) magnetic resonance imaging for assessment of kidney iron overload in thalassemic patients.
    Hashemieh M; Azarkeivan A; Akhlaghpoor S; Shirkavand A; Sheibani K
    Arch Iran Med; 2012 Feb; 15(2):91-4. PubMed ID: 22292579
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal iron deposition by magnetic resonance imaging in pediatric β-thalassemia major patients: Relation to renal biomarkers, total body iron and chelation therapy.
    ElAlfy MS; Khalil Elsherif NH; Ebeid FSE; Ismail EAR; Ahmed KA; Darwish YW; Ibrahim AS; Elghamry IRF; Shokrey NA; Alajeil DN
    Eur J Radiol; 2018 Jun; 103():65-70. PubMed ID: 29803388
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum Hepcidin as a Diagnostic Marker of Severe Iron Overload in Beta-thalassemia Major.
    Kaddah AM; Abdel-Salam A; Farhan MS; Ragab R
    Indian J Pediatr; 2017 Oct; 84(10):745-750. PubMed ID: 28600663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of Iron Overload Between Age Groups Using Magnetic Resonance Imaging and Its Correlation with Iron Profile in Transfusion-dependent Thalassemia.
    Wahidiyat PA; Iskandar SD; Sekarsari D
    Acta Med Indones; 2018 Jul; 50(3):230-236. PubMed ID: 30333273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patterns of liver iron accumulation in patients with sickle cell disease and thalassemia with iron overload.
    Hankins JS; Smeltzer MP; McCarville MB; Aygun B; Hillenbrand CM; Ware RE; Onciu M
    Eur J Haematol; 2010 Jul; 85(1):51-7. PubMed ID: 20374273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deferasirox effectively decreases iron burden in patients with double heterozygous HbS/β-thalassemia.
    Voskaridou E; Plata E; Douskou M; Sioni A; Mpoutou E; Christoulas D; Dimopoulou M; Terpos E
    Ann Hematol; 2011 Jan; 90(1):11-5. PubMed ID: 20661572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.